AbbVie says FDA reviews Skyrizi subcutaneous induction dosing for Crohn’s disease
Bitget2026/10/13 19:15- AbbVie said subcutaneous induction dosing for Crohn’s drug Skyrizi is under regulatory review by the FDA and EMA.
- The company cited Phase 3 AFFIRM data showing week 24 endoscopic remission of 35.8% on Skyrizi vs 9.1% on placebo.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stock futures fluctuate by $650 billions due to news related to Jensen Huang
Nikkei Average Index gains expand to 2.78%
Surprise! Japan intervened in the forex market three times this summer, selling a record 154 trillion yen in three days
Japan has confirmed that it intervened in the foreign exchange market three times this summer, buying yen to support the exchange rate, corroborating earlier market reports. This included the first joint intervention with the United States to support the yen in nearly thirty years.
UBS CEO warns: A Democratic sweep could slow down AI capacity building, valuation concerns are "very important"
UBS CEO Ermotti stated that the U.S. midterm elections may slow down AI capacity building and that the valuations are questionable; he also warned of persistent inflation and the risk of contagion in the European bond market.
Crypto prices
More
